Randomized Trialhigh evidence
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.
JAMA cardiology·June 17, 2026·PMID 42307914
Why it mattersThis trial provides rigorous, head-to-head evidence that aficamten monotherapy offers superior exercise performance across multiple domains compared with metoprolol, the current first-line β-blocker for oHCM. It challenges the expert-opinion-based guideline recommendation and supports aficamten as a more effective option for improving functional capacity in symptomatic patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled